Assertio Spring 2022 Investor Presentation - Specialty Pharmaceuticals

Assertio presents Spring 2022 updates on its specialty pharmaceutical business, highlighting a major restructuring achieving $45 million in annual savings and a new management team. The company reports its first acquisition since 2015 (Otrexup from Antares) and marks the fourth consecutive quarter of positive cash flow, with 2022 net sales guidance of $126–$136 million.